Tratamiento del edema macular diabético con ranibizumab intravítreo (Lucentis): resultados en práctica clínica habitualntravitreal ranibizumab (Lucentis) for the treament of diabetic macular edema: clinical setting practice results
- Abreu González, Rodrigo
- Pérez Méndez, L.
- Solé González, Lorena
- Alonso Plasencia, Marta
- Gil Hernández, María Antonia
- Abreu Reyes, Pedro
ISSN: 0211-2698
Year of publication: 2014
Issue: 25
Pages: 41-45
Type: Article
More publications in: Archivos de la Sociedad Canaria de Oftalmología
Abstract
Purpose: We analyze the results of intravitreal ranibizumab monotherapy for the treatment of diabetic macular edema in the clinical setting. Methods: This is an observational, retrospective, single-centered study reviewing medical records of patients with diabetic macular edema, treated according to standard clinical practice of intravitreal ranibizumab monotherapy. We study the cases between August 2012 and August 2013, in Hospital Universitario La Candelaria in Tenerife. The visual acuity and OCT results are classified in three groups: improvement, stability and worsening. Results: The study includes 130 eyes (106 patients); 70 ( 53.8%) women and 60 (46.2%) men with a mean age of 68±11 years. The follow-up media is 6 months, with a mean of 6,91±3,52 months (range 2.12 months). The mean HbA1c of the enrolled patients is 7.4±1.76% (range 4.4-11.7%). The mean value of best corrected visual acuity (BCVA) at baseline examination is 0.34 (logMAR ), remaining unchanged with no statistically significant values throughout the follow-up. The mean central subfield macular thickness (CSMT) at the baseline examination is 427±133 microns and 359±120 microns at final examination ( p<0.05). A single case of endophthalmitis following intravitreal injection of ranibizumab is detected. Conclusions: Our experience with ranibizumab in the treatment of diabetic macular edema is positive and has proved safe, although it is far from the results of clinical trials.